Boehringer snags FDA nod on inhaled COPD drug; Grad student develops genetic cancer-drug delivery system;

> An FDA panel gave the go-ahead for Boehringer Ingelheim's once-daily, inhaled COPD drug olodaterol for the treatment of chronic lung disease. Story

> A Virginia Tech graduate student is developing a DNA- and RNA-based drug delivery system that targets genetic diseases and cancer. Release

> Generex Biotechnology of Canada has submitted 12-week Phase III trial results for its oral insulin Generex Oral-lyn to the Indian government for approval. Item

> Researchers in China have found that microparticles with incorporated proteins can be used as a carrier that allows for sustained drug release. Abstract

> Echo Therapeutics ($ECTE) looks to gain approval of its Symphony needle-free transdermal glucose-monitoring system after presenting positive clinical trial results. Release

> Gilead Sciences has initiated a Phase III clinical study of a once-daily, single-tablet regimen to treat HIV. Release